• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原子力显微镜成像揭示了ADAMTS13的多种构象状态。

AFM Imaging Reveals Multiple Conformational States of ADAMTS13.

作者信息

Yu Shanshan, Liu Wang, Fang Jinhua, Shi Xiaozhong, Wu Jianhua, Fang Ying, Lin Jiangguo

机构信息

Institute of Biomechanics, School of Biosciences and Bioengineering, South China University of Technology, Guangzhou, 510006 China.

出版信息

J Biol Eng. 2019 Jan 22;13:9. doi: 10.1186/s13036-018-0102-y. eCollection 2019.

DOI:10.1186/s13036-018-0102-y
PMID:30679946
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6343300/
Abstract

BACKGROUND

ADAMTS13 (A disintegrin and metalloprotease with a thrombospondin type 1 motif 13) cleaves Von Willebrand factor (VWF) to regulate its size, thereby preventing aberrant platelet aggregation and thrombus. Deficiency of ADAMTS13 caused by either genetic mutations or by inhibitory autoantibodies against ADAMTS13 leads to thrombotic thrombocytopenic purpura (TTP). Recently, ADAMTS13 was reported to adopt a "closed" conformation with lower activity and an "open" one resulting from the engagements of VWF D4-CK domains or antibodies to the distal domains of ADAMTS13, or mutations in its spacer domain. These engagements or mutations increase ADAMTS13 activity by ~ 2.5-fold. However, it is less known whether the conformation of ADAMTS13 is dynamic or stable.

RESULTS

Wild type ADAMTS13 (WT-ADAMTS13) and the gain-of-function variant (GOF-ADAMTS13) with five mutations (R568K / F592Y / R660K / Y661F / Y665F) in spacer domain were imaged by atomic force microscopy (AFM) at pH 6 and pH 7.5. The data revealed that at both pH 6 and pH 7.5, WT-ADAMTS13 adopted two distinct conformational states (state I and state II), while an additional state (state III) was observed in GOF-ADAMTS13. In the present study, we propose that state I is the "closed" conformation, state III is the "open" one, and state II is an intermediate one. Comparing to pH 7.5, the percentages of state II of WT-ADAMTS13 and state III of GOF-ADAMTS13 increased at pH 6, with the decrease in the state I for WT-ADAMTS13 and state I and state II for GOF-ADAMTS13, suggesting lower pH extended the conformation of ADAMTS13.

CONCLUSION

Both WT- and GOF-ADAMTS13 exist multiple conformational states and lower pH might alter the tertiary structure and/or disrupt the intra-domain interactions, increasing the flexibility of ADAMTS13 molecules.

摘要

背景

ADAMTS13(含Ⅰ型血小板反应蛋白基序的解聚素样金属蛋白酶13)可裂解血管性血友病因子(VWF)以调节其大小,从而防止异常的血小板聚集和血栓形成。由基因突变或针对ADAMTS13的抑制性自身抗体引起的ADAMTS13缺乏会导致血栓性血小板减少性紫癜(TTP)。最近有报道称,ADAMTS13会呈现活性较低的“闭合”构象以及因VWF D4-CK结构域与ADAMTS13远端结构域结合、抗体结合或其间隔区突变而产生的“开放”构象。这些结合或突变使ADAMTS13的活性增加约2.5倍。然而,对于ADAMTS13的构象是动态的还是稳定的,人们了解较少。

结果

在pH 6和pH 7.5条件下,通过原子力显微镜(AFM)对野生型ADAMTS13(WT-ADAMTS13)和间隔区有五个突变(R568K / F592Y / R660K / Y661F / Y665F)的功能获得性变体(GOF-ADAMTS13)进行成像。数据显示,在pH 6和pH 7.5时,WT-ADAMTS13均呈现两种不同的构象状态(状态Ⅰ和状态Ⅱ),而在GOF-ADAMTS13中观察到了另外一种状态(状态Ⅲ)。在本研究中,我们提出状态Ⅰ是“闭合”构象,状态Ⅲ是“开放”构象,状态Ⅱ是中间构象。与pH 7.5相比,WT-ADAMTS13的状态Ⅱ和GOF-ADAMTS13的状态Ⅲ在pH 6时的百分比增加,而WT-ADAMTS13的状态Ⅰ以及GOF-ADAMTS13的状态Ⅰ和状态Ⅱ的百分比降低,这表明较低的pH值扩展了ADAMTS13的构象。

结论

WT-ADAMTS13和GOF-ADAMTS13均存在多种构象状态,较低的pH值可能会改变三级结构和/或破坏结构域内相互作用,增加ADAMTS13分子的灵活性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c581/6343300/a495ee855ebb/13036_2018_102_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c581/6343300/e302a63fceea/13036_2018_102_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c581/6343300/ee66925817da/13036_2018_102_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c581/6343300/e3809dbf87b0/13036_2018_102_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c581/6343300/a495ee855ebb/13036_2018_102_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c581/6343300/e302a63fceea/13036_2018_102_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c581/6343300/ee66925817da/13036_2018_102_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c581/6343300/e3809dbf87b0/13036_2018_102_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c581/6343300/a495ee855ebb/13036_2018_102_Fig4_HTML.jpg

相似文献

1
AFM Imaging Reveals Multiple Conformational States of ADAMTS13.原子力显微镜成像揭示了ADAMTS13的多种构象状态。
J Biol Eng. 2019 Jan 22;13:9. doi: 10.1186/s13036-018-0102-y. eCollection 2019.
2
Conformational activation of ADAMTS13.ADAMTS13的构象激活
Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18578-83. doi: 10.1073/pnas.1411979112. Epub 2014 Dec 15.
3
Enhanced activity of an ADAMTS-13 variant (R568K/F592Y/R660K/Y661F/Y665F) against platelet agglutination in vitro and in a murine model of acute ischemic stroke.体外和急性缺血性脑卒中小鼠模型中,ADAMTS-13 变异体(R568K/F592Y/R660K/Y661F/Y665F)对血小板聚集的活性增强。
J Thromb Haemost. 2018 Nov;16(11):2289-2299. doi: 10.1111/jth.14275. Epub 2018 Oct 24.
4
Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.获得功能的 ADAMTS13 变异体,对获得性血栓性血小板减少性紫癜患者针对 ADAMTS13 的自身抗体具有抗性。
Blood. 2012 Apr 19;119(16):3836-43. doi: 10.1182/blood-2011-12-399501. Epub 2012 Jan 30.
5
Residues R1075, D1090, R1095, and C1130 Are Critical in ADAMTS13 TSP8-Spacer Interaction Predicted by Molecular Dynamics Simulation.残基 R1075、D1090、R1095 和 C1130 是通过分子动力学模拟预测的 ADAMTS13-TSP8 间隔子相互作用中的关键残基。
Molecules. 2021 Dec 12;26(24):7525. doi: 10.3390/molecules26247525.
6
Characterization of the interactions of ADAMTS13 CUB1 domain to WT- and GOF-Spacer domain by molecular dynamics simulation.通过分子动力学模拟对 ADAMTS13 CUB1 结构域与 WT- 和 GOF-Spacer 结构域相互作用的特性进行研究。
J Mol Graph Model. 2021 Dec;109:108029. doi: 10.1016/j.jmgm.2021.108029. Epub 2021 Sep 6.
7
Conformational quiescence of ADAMTS-13 prevents proteolytic promiscuity.ADAMTS-13的构象静止可防止蛋白水解的杂乱性。
J Thromb Haemost. 2016 Oct;14(10):2011-2022. doi: 10.1111/jth.13445. Epub 2016 Sep 23.
8
Interplay between ADAMTS13 and von Willebrand factor in inherited and acquired thrombotic microangiopathies.遗传性和获得性血栓性微血管病中ADAMTS13与血管性血友病因子的相互作用
Semin Hematol. 2005 Jan;42(1):56-62. doi: 10.1053/j.seminhematol.2004.09.008.
9
Measurement of ADAMTS13.ADAMTS13的测定
Int Rev Thromb. 2006;1(4):272-280.
10
Conformational plasticity of ADAMTS13 in hemostasis and autoimmunity.ADAMTS13 在止血和自身免疫中的构象可塑性。
J Biol Chem. 2021 Oct;297(4):101132. doi: 10.1016/j.jbc.2021.101132. Epub 2021 Aug 27.

引用本文的文献

1
Open or closed? Understanding the molecular mechanisms and clinical implications of ADAMTS13's conformation.开放还是封闭?了解ADAMTS13构象的分子机制及临床意义。
Hemasphere. 2025 Jul 27;9(7):e70189. doi: 10.1002/hem3.70189. eCollection 2025 Jul.
2
The Force-Dependent Mechanism of an Integrin α4β7-MAdCAM-1 Interaction.整合素 α4β7 与 MAdCAM-1 相互作用的力依赖性机制。
Int J Mol Sci. 2023 Nov 7;24(22):16062. doi: 10.3390/ijms242216062.
3
[Effects of material interfaces on orientation and function of fibrinogen].[材料界面对纤维蛋白原取向和功能的影响]

本文引用的文献

1
An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura.ADAMTS-13 的开放构象是急性获得性血栓性血小板减少性紫癜的一个标志。
J Thromb Haemost. 2018 Feb;16(2):378-388. doi: 10.1111/jth.13922. Epub 2018 Jan 23.
2
vWF/ADAMTS13 is associated with on-aspirin residual platelet reactivity and clinical outcome in patients with stable coronary artery disease.血管性血友病因子裂解酶(vWF/ADAMTS13)与稳定型冠状动脉疾病患者的阿司匹林抵抗性残余血小板反应性及临床结局相关。
Thromb J. 2017 Nov 22;15:28. doi: 10.1186/s12959-017-0151-3. eCollection 2017.
3
ADAMTS-13 and von Willebrand factor: a dynamic duo.
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2021 Dec 25;38(6):1087-1096. doi: 10.7507/1001-5515.202102018.
4
Residues R1075, D1090, R1095, and C1130 Are Critical in ADAMTS13 TSP8-Spacer Interaction Predicted by Molecular Dynamics Simulation.残基 R1075、D1090、R1095 和 C1130 是通过分子动力学模拟预测的 ADAMTS13-TSP8 间隔子相互作用中的关键残基。
Molecules. 2021 Dec 12;26(24):7525. doi: 10.3390/molecules26247525.
5
A human monoclonal antibody against the distal carboxyl terminus of ADAMTS-13 modulates its susceptibility to an inhibitor in thrombotic thrombocytopenic purpura.一种针对 ADAMTS-13 远端羧基末端的人源单克隆抗体调节其对血栓性血小板减少性紫癜抑制剂的敏感性。
J Thromb Haemost. 2021 Aug;19(8):1888-1895. doi: 10.1111/jth.15332. Epub 2021 May 11.
6
Insights Into Immunothrombosis: The Interplay Among Neutrophil Extracellular Trap, von Willebrand Factor, and ADAMTS13.免疫血栓形成的新见解:中性粒细胞胞外诱捕网、血管性血友病因子与 ADAMTS13 的相互作用。
Front Immunol. 2020 Dec 2;11:610696. doi: 10.3389/fimmu.2020.610696. eCollection 2020.
7
A Single Synonymous Variant (c.354G>A [p.P118P]) in Confers Enhanced Specific Activity.一个同义突变(c.354G>A [p.P118P])可增强其特定活性。
Int J Mol Sci. 2019 Nov 15;20(22):5734. doi: 10.3390/ijms20225734.
8
ADAMTS13: An Emerging Target in Stroke Therapy.ADAMTS13:卒中治疗中的新兴靶点。
Front Neurol. 2019 Jul 17;10:772. doi: 10.3389/fneur.2019.00772. eCollection 2019.
ADAMTS-13 和血管性血友病因子:一对动态组合。
J Thromb Haemost. 2018 Jan;16(1):6-18. doi: 10.1111/jth.13898. Epub 2017 Dec 2.
4
Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura.重组ADAMTS-13:先天性血栓性血小板减少性紫癜的首次人体药代动力学和安全性研究
Blood. 2017 Nov 9;130(19):2055-2063. doi: 10.1182/blood-2017-06-788026. Epub 2017 Sep 14.
5
Pathophysiology of thrombotic thrombocytopenic purpura.血栓性血小板减少性紫癜的病理生理学
Blood. 2017 Sep 7;130(10):1181-1188. doi: 10.1182/blood-2017-04-636431. Epub 2017 Aug 2.
6
Accurate nanoscale flexibility measurement of DNA and DNA-protein complexes by atomic force microscopy in liquid.利用原子力显微镜在液相中对 DNA 及其与蛋白质复合物进行精确的纳米级柔顺性测量
Nanoscale. 2017 Aug 10;9(31):11327-11337. doi: 10.1039/c7nr04231k.
7
Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics.血栓性血小板减少性紫癜:发病机制、诊断和潜在的新型治疗方法。
J Thromb Haemost. 2017 Oct;15(10):1889-1900. doi: 10.1111/jth.13764. Epub 2017 Jul 27.
8
The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy.血管性血友病因子在血管炎症中的作用:从发病机制到靶向治疗
Mediators Inflamm. 2017;2017:5620314. doi: 10.1155/2017/5620314. Epub 2017 May 28.
9
Thrombotic thrombocytopenic purpura.血栓性血小板减少性紫癜。
Blood. 2017 May 25;129(21):2836-2846. doi: 10.1182/blood-2016-10-709857. Epub 2017 Apr 17.
10
A model for the conformational activation of the structurally quiescent metalloprotease ADAMTS13 by von Willebrand factor.一种由血管性血友病因子介导的结构静止型金属蛋白酶ADAMTS13构象激活模型。
J Biol Chem. 2017 Apr 7;292(14):5760-5769. doi: 10.1074/jbc.M117.776732. Epub 2017 Feb 16.